GlobeNewswire
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
📈
AI Sentiment
Highly Positive
8/10
- Home
- ANVS
ANVS
Annovis Bio Inc.
as of 12-09-2025 4:00pm EST
$4.46
+$0.16
+3.72%
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Chart Type:
Time Range:
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 53.3M | IPO Year: | 2020 |
| Target Price: | $13.50 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $6.37 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ANVS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.59%
69.59%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Annovis Bio Inc. (ANVS)
Hoffman Michael B
Buy
Director
ANVS Nov 24, 2025
Avg Cost/Share
$4.07
Shares
39,200
Total Value
$159,886.07
Owned After
2,482,028
Hoffman Michael B
Buy
Director
ANVS Nov 14, 2025
Avg Cost/Share
$2.11
Shares
15,000
Total Value
$31,650.00
Owned After
2,482,028
SEC Form 4
Maccecchini Maria-Luisa
Buy
President & CEO
ANVS Oct 28, 2025
Avg Cost/Share
$2.05
Shares
97,561
Total Value
$200,000.05
Owned After
1,212,020
SEC Form 4
Hoffman Michael B
Buy
Director
ANVS Oct 28, 2025
Avg Cost/Share
$2.05
Shares
975,610
Total Value
$2,000,000.50
Owned After
2,482,028
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hoffman Michael B | ANVS | Director | Nov 24, 2025 | Buy | $4.07 | 39,200 | $159,886.07 | 2,482,028 | |
| Hoffman Michael B | ANVS | Director | Nov 14, 2025 | Buy | $2.11 | 15,000 | $31,650.00 | 2,482,028 | |
| Maccecchini Maria-Luisa | ANVS | President & CEO | Oct 28, 2025 | Buy | $2.05 | 97,561 | $200,000.05 | 1,212,020 | |
| Hoffman Michael B | ANVS | Director | Oct 28, 2025 | Buy | $2.05 | 975,610 | $2,000,000.50 | 2,482,028 |
Latest Annovis Bio Inc. News
ANVS Breaking Stock News: Dive into ANVS Ticker-Specific Updates for Smart Investing
Compare ANVS vs Leading Stocks
See how ANVS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANVS Annovis Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.